Scholar Rock (SRRK) Set to Announce Quarterly Earnings on Tuesday

Scholar Rock (NASDAQ:SRRK) is set to release its earnings data before the market opens on Tuesday, November 12th. Analysts expect Scholar Rock to post earnings of ($0.60) per share for the quarter. Investors that are interested in participating in the company’s conference call can do so using this link.

Scholar Rock (NASDAQ:SRRK) last announced its earnings results on Thursday, August 8th. The company reported ($0.60) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.61) by $0.01. During the same quarter in the previous year, the firm earned ($0.47) EPS. On average, analysts expect Scholar Rock to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Scholar Rock Trading Up 0.4 %

SRRK opened at $29.08 on Monday. The stock has a 50-day moving average of $18.76 and a 200 day moving average of $13.15. The company has a current ratio of 6.04, a quick ratio of 6.04 and a debt-to-equity ratio of 0.36. Scholar Rock has a 12 month low of $6.76 and a 12 month high of $35.38. The firm has a market cap of $2.33 billion, a P/E ratio of -13.10 and a beta of 0.47.

Insider Transactions at Scholar Rock

In other Scholar Rock news, Director Srinivas Akkaraju sold 1,175,713 shares of the business’s stock in a transaction dated Monday, October 7th. The shares were sold at an average price of $29.25, for a total value of $34,389,605.25. Following the completion of the sale, the director now directly owns 5,612,896 shares of the company’s stock, valued at $164,177,208. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In other Scholar Rock news, CFO Edward H. Myles sold 206,240 shares of Scholar Rock stock in a transaction on Monday, October 7th. The stock was sold at an average price of $26.56, for a total transaction of $5,477,734.40. Following the completion of the sale, the chief financial officer now directly owns 161,088 shares of the company’s stock, valued at $4,278,497.28. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Srinivas Akkaraju sold 1,175,713 shares of the stock in a transaction on Monday, October 7th. The stock was sold at an average price of $29.25, for a total value of $34,389,605.25. Following the transaction, the director now directly owns 5,612,896 shares in the company, valued at $164,177,208. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 1,415,340 shares of company stock worth $40,666,088. Insiders own 19.20% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on the company. JPMorgan Chase & Co. boosted their price objective on Scholar Rock from $18.00 to $31.00 and gave the stock an “overweight” rating in a research note on Monday, October 14th. HC Wainwright boosted their price objective on Scholar Rock from $30.00 to $35.00 and gave the stock a “buy” rating in a research note on Monday, October 7th. Wedbush restated an “outperform” rating and issued a $37.00 target price on shares of Scholar Rock in a report on Monday, November 4th. BMO Capital Markets upped their price target on shares of Scholar Rock from $34.00 to $38.00 and gave the company an “outperform” rating in a report on Friday, October 11th. Finally, Piper Sandler increased their price objective on shares of Scholar Rock from $28.00 to $42.00 and gave the stock an “overweight” rating in a research report on Tuesday, October 15th. Six equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, Scholar Rock has an average rating of “Buy” and an average target price of $33.29.

Scholar Rock Company Profile

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.